Novonesis (Novozymes) B (OCSE:NSIS B) Total Current Assets : kr13,491 Mil (As of Jun. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Novonesis (Novozymes) B Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Novonesis (Novozymes) B's total current assets for the quarter that ended in Jun. 2024 was kr13,491 Mil.

Novonesis (Novozymes) B Total Current Assets Historical Data

The historical data trend for Novonesis (Novozymes) B's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Total Current Assets Chart

Novonesis (Novozymes) B Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

7,048.29

6,909.38

7,821.83

9,226.86

9,472.50

Novonesis (Novozymes) B Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Jun24
Total Current Assets	Get a 7-Day Free Trial															9,583.57	9,371.61	9,420.47	9,472.50	13,491.04

Novonesis (Novozymes) B Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Novonesis (Novozymes) B's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1157.28	+	4055.496	+	3631.023	+	628.697
	=	9,472

Novonesis (Novozymes) B's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	1963.649	+	5976.778	+	5130.416	+	420.196
	=	13,491

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Novonesis (Novozymes) B (OCSE:NSIS B) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Novonesis (Novozymes) B's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1963.649	-	31699.016	+	0.75 * 5086.381	+	0.5 * 5130.416
=	-23,355

Novonesis (Novozymes) B Total Current Assets Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Novonesis (Novozymes) B Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OCSE:NSIS B) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

NVZMY:USA NVZMF:USA NSISBc:UK 0Q4U:UK NZM2:Germany

Address

Krogshoejvej 36, Bagsvaerd, DNK, 2880

Website

https://www.novozymes.com

Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

No Headlines